Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPECTRA: PIPAC in Advanced Gastric Cancer
NCT05318794Phase 2Not yet recruiting
- Sponsor
- Imperial College London
- Start
- Nov 2023
- Primary completion
- Jul 2025
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin and cisplatin in gastric cancer (GC), sponsored by Imperial College London. Primary endpoint: Feasibility and safety of combined neoadjuvant systemic chemotherapy and pressurised intraperitoneal aerosol chemotherapy (PIPAC) at 2 years. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
doxorubicincisplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05318794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05318794.